- Home
- ETJ vs EYPT Comparison
ETJ vs EYPT Comparison
Compare ETJ & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETJ
- EYPT
- Stock Information
- Founded
- ETJ 2007
- EYPT 1987
- Country
- ETJ United States
- EYPT United States
- Employees
- ETJ N/A
- EYPT N/A
- Industry
- ETJ Finance Companies
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- ETJ Finance
- EYPT Industrials
- Exchange
- ETJ Nasdaq
- EYPT Nasdaq
- Market Cap
- ETJ 623.9M
- EYPT 489.4M
- IPO Year
- ETJ N/A
- EYPT 2005
- Fundamental
- Price
- ETJ $9.17
- EYPT $7.24
- Analyst Decision
- ETJ
- EYPT Strong Buy
- Analyst Count
- ETJ 0
- EYPT 8
- Target Price
- ETJ N/A
- EYPT $25.71
- AVG Volume (30 Days)
- ETJ 175.6K
- EYPT 665.0K
- Earning Date
- ETJ 01-01-0001
- EYPT 03-06-2025
- Dividend Yield
- ETJ 8.30%
- EYPT N/A
- EPS Growth
- ETJ N/A
- EYPT N/A
- EPS
- ETJ N/A
- EYPT N/A
- Revenue
- ETJ N/A
- EYPT $45,713,000.00
- Revenue This Year
- ETJ N/A
- EYPT N/A
- Revenue Next Year
- ETJ N/A
- EYPT N/A
- P/E Ratio
- ETJ N/A
- EYPT N/A
- Revenue Growth
- ETJ N/A
- EYPT 7.50
- 52 Week Low
- ETJ $7.20
- EYPT $6.90
- 52 Week High
- ETJ $8.47
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- ETJ 44.49
- EYPT 41.66
- Support Level
- ETJ $9.08
- EYPT $7.58
- Resistance Level
- ETJ $9.35
- EYPT $8.16
- Average True Range (ATR)
- ETJ 0.11
- EYPT 0.55
- MACD
- ETJ -0.00
- EYPT -0.07
- Stochastic Oscillator
- ETJ 30.00
- EYPT 3.06
About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.